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Abstract
Background: There are few reports of the efficacy of adalimumab (ADA) for clinical remission and preventing
postoperative recurrence in Crohn's disease (CD) in Asian real practice settings. We conducted a Japanese multicenter
retrospective observational study.
Methods: We evaluated patients with CD who were treated with ADA at 11 medical institutions in Japan to
investigate the clinical efficacy of remission up to 52 weeks and the associated factors to achieve remission with
a CD Activity Index (CDAI) < 150. The effects of preventing postoperative recurrence were also evaluated.
Results: In 62 patients, the remission rates were 33.9, 74.2, 75.8, 77.4, and 66.1 % at 0, 4, 12, 26, and 52 weeks,
respectively. Although 10 patients discontinued treatment due to primary nonresponse, secondary nonresponse,
or adverse events, the ongoing treatment rate at 52 weeks was 83.9 %. Comparison of remission and non-remission on
univariate analysis identified colonic type and baseline CDAI value as significant associated factors (P < 0.05). In 16
patients who received ADA to prevent postoperative recurrence, the clinical remission maintenance rate was 93.8 %
and the mucosal healing rate was 64.3 % during a mean postoperative follow-up period of 32.3 months.
Conclusions: ADA effectively induced remission and prevented postoperative recurrence in patients with CD in a real
practice setting.
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Background
Crohn's disease (CD), an inflammatory bowel disease
(IBD), is an intractable disease of unknown etiology [1].
CD is progressive and markedly impairs patient quality
of life due to its associated symptoms such as diarrhea,
abdominal pain, fever, and surgery [2–4]. Although there
is currently no cure for CD, the inflammatory cytokine
tumor necrosis factor-α (TNF-α) is involved in clinical
condition [5], against which anti-TNF-α monoclonal
antibody (anti-TNF-α antibody) is highly effective [6, 7].
For the treatment of CD, infliximab (IFX), a chimeric
antibody and infusion drug, first appeared as an anti-
TNF-α antibody, followed by adalimumab (ADA), a fully
humanized antibody and subcutaneous drug. IFX and
ADA were highly effective in large-scale studies and
have already been widely used worldwide [8–15].
Although the clinical features of CD in Asia is relatively
similar to that of North America or Europe, there are
some differences such as a higher prevalence of males and
ileo-colonic type, less familial clustering, extra-intestinal
manifestations, and surgical rates. As for genetics, nu-
cleotide oligomerization domain-2 (NOD2) variants and
autophagy-related 16-like 1(ATG16L1) variants, which
have been firmly associated with CD in the West have not
been detected in the patients with CD in Asia [16]. Taking
account of these differences, the data from Asia is import-
ant in spite of the numerous data from West. However,
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ADA received approval later in Asian countries including
Japan than in the Europe and US; therefore, there are
limited reports on its efficacy in Asian real practice set-
tings [17–20]. Watanabe et al. reported that clinical re-
mission rate at week 4 in the induction therapy was
33.3 %. Seventy percentage of patients achieved decrease
in CDAI ≥ 70 points and the rest was unresponsive at
week 4 in the induction therapy [17]. Furthermore, intes-
tinal resection is commonly required in patients with CD
and often leads to repeated surgery; thus, it is important
to prevent postoperative recurrence [21, 22]. Recent re-
ports indicated that IFX and ADA effectively prevent post-
operative recurrence [23–26]. However, no report to date
has demonstrated the ability of ADA to prevent postoper-
ative recurrence in Asia. Under these circumstances, we
conducted a multicenter observational study in Japan to
evaluate ADA efficacy and safety as well as its ability to




The Nagasaki observational study of adalimumab is a
multicenter retrospective observational study of patients
with IBD receiving ADA treatment at a total of 11 med-
ical sites including Nagasaki University Hospital and its
related facilities. This study was reviewed and approved
by the Nagasaki University Hospital Ethics Committee
before its initiation.
Patients
The study included all patients who received ADA for
the treatment of CD at a total of 11 study sites including
Nagasaki University Hospital and its related facilities be-
tween November 2010 and January 2014. Patients who
failed to complete 52 weeks of follow-up due to relocat-
ing were excluded from the analysis.
Treatment protocol
ADA was administered at an initial dose of 160 mg and
a second dose of 80 mg with a 2-week induction interval.
Thereafter, ADA 40 mg was administered every other
week as maintenance therapy. ADA dose intensification
was not included in this study because it is not currently
approved in Japan.
Data collection
A shared common database was used to collect demo-
graphic and clinical data. Data collected at baseline were
sex, age, disease duration, disease extension, history of op-
eration, smoking habits, concomitant fistula or anal lesion,
previous infliximab therapy, concomitant medications or
elemental diet at baseline, C-reactive protein (CRP) levels,
and the Crohn’s disease activity index (CDAI) [27].
Clinical activity was evaluated using the CDAI after 4, 12,
26, and 52 weeks of treatment. The date of and reason for
ADA discontinuation, requirement of further rescue
therapy, and adverse events were also recorded.
Definition
We defined remission as a CDAI < 150. Non-remission
was defined as discontinuation due to a lack of efficacy,
adverse event, or other reason. In addition, we evaluated
the ability of ADA to prevent postoperative recurrence
in patients with any recurrence risk factor [28] such as
smoking, penetrating disease, history of prior resection,
and short disease duration (<10 years) after intestinal re-
section. Clinical remission was defined as a CDAI < 150,
and mucosal healing was confirmed by a Rutgeerts score
of i0 or i1 [29].
Endpoints
The primary endpoints of the study were rates of clinical
remission at 4, 12, 26, and 52 weeks in the intention-to-
treat (ITT) population, and the proportion of patients
still receiving ADA therapy at the end of the first year.
The secondary endpoints included the maintenance rate
of clinical remission and mucosal healing in the patients
who received ADA treatment for the prevention of post-
operative recurrence.
Statistical analysis
All efficacy analyses were performed on an ITT basis.
Statistical analysis was performed with a Chi-square test
or Fisher's exact test for categorical data and Student’s
t-test or the Mann-Whitney U-test for continuous vari-
ables. Factors identified as having significant differences
on univariate analysis were further assessed by multi-
variate analysis with logistic regression. P values < 0.05
were considered statistically significant.
Results
Patient demographics
Of 71 patients who received ADA treatment during the
study period, 62 were included in the analysis set, while
the other nine were excluded: three who failed to
complete follow-up due to transfer to another hospital be-
fore 52 weeks, five who missed the CDAI evaluation, and
one who intentionally withdrew from treatment due to
pregnancy (Fig. 1). The baseline characteristics of the 62
patients are shown in Table 1. The mean age was
33.1 years, 74.2 % of the patients were men, the median
disease duration was 96 months, and 32.3 % of the pa-
tients had a disease duration < 2 years. Prior treatment
consisted of IFX in 53.2 % of the patients; of them 33.3 %
were on a double IFX dose (10 mg/kg). The mean baseline
CDAI was 185.1 points, and 33.9 % of the patients had a
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CDAI < 150 before ADA treatment, including those who
required a medication switch due to IFX intolerance.
Clinical efficacy
In all 62 patients, the remission rates were 33.9, 74.2,
75.8, 77.4, and 66.1 % at 0, 4, 12, 26, and 52 weeks, re-
spectively (Fig. 2a). In the 41 patients whose baseline
CDAI was ≥150, the remission rates were 63.4, 70.7,
75.6, and 56.1 % at 4, 12, 26, and 52 weeks, respectively
(Fig. 2b). Of the 62 patients, 10 discontinued treatment
due to primary nonresponse (PNR) (n = 1), secondary
nonresponse (SNR) (n = 2), or adverse event (n = 7). The
ongoing ADA treatment rate at 52 week was 83.9 %
(Fig. 3).
Efficacy predictor
An univariate analysis was performed to compare 41 pa-
tients who achieved remission at 52 weeks of ADA treat-
ment (remission group) with 21 patients who failed to
achieve remission with a CDAI ≥ 150 or discontinued
ADA treatment before 52 weeks (non-remission group)
(Table 2). Significant differences between groups were
detected only for the colonic type (P = 0.0387) and base-
line CDAI (P = 0.0236). The remission group had a
slightly lower median disease duration and included more
patients with a disease duration < 2 years, but the differ-
ence was not statistically significant. A multivariate ana-
lysis was performed for the two factors, colonic type and
baseline CDAI, identified significant differences from the
univariate analysis, but both were not found to be signifi-
cant (Table 3).
Prevention of postoperative recurrence
The baseline characteristics, presence of risk factors, clin-
ical remission after ADA treatment, and mucosal healing
by endoscopy of the 16 high-risk patients who received
ADA treatment for the prevention of postoperative recur-
rence after intestinal resection are shown in Table 4. Each
patient had an average of 2.1 of four recurrence risk
factors including smoking, penetrating disease, previous
resection, and disease duration < 10 years. The mainten-
ance rate of clinical remission up to the last observation
period (a mean of 32.3 months) was 93.8 % (15/16 pa-
tients). Endoscopy was performed in 14 patients at a mean
25.3 months, and mucosal healing was confirmed in
64.3 % (9/14 patients). Clinical remission was confirmed
in four of five patients who experienced endoscopic re-
lapse. Of the three patients whose relapse was confirmed
with a Rutgeerts score of i3 or i4, two had experience with
Patients who received ADA
(n=71)
Patients in the analysis set
(n=62)
Nine patients were excluded.
Transfer to another hospital before 52 weeks (n=3)
missed the CDAI evaluation (n=5)










52 weeks of follow-up
Fig. 1 Flowchart of patient disposition. ADA; adalimumab, CDAI;
Crohn’s Disease Activity Index, PNR; primary nonresponse, SNR;
secondary nonresponse, AE; adverse event
Table 1 Patients’ baseline characteristics
Patient number 62
Age (years) 33.1 ± 10.3
Gender (male) 74.2 % (46/72)
Disease duration (months) 96.0 (0.0–480.0)
Disease duration < 2 years 32.3 % (20/62)
Disease location
Ileo 14.5 % (9/62)
Ileocolonic 74.2 % (46/62)
Colonic 11.3 % (7/62)
Surgery required 62.9 % (39/63)
Extra fistula 34.4 % (21/61)
Intra fistula 8.2 % (5/61)
Perianal disease 48.4 % (30/62)
Smoking 17.3 % (9/52)
Concomitant use
5-Aminosalicylates 91.9 % (57/62)
Steroids 9.7 % (6/62)
Immunomodulators 24.2 % (15/62)
Elemental diet 62.9 % (39/62)
IFX experience
Experience with IFX 53.2 % (33/62)
Double dose 33.3 % (11/33)
Duration of IFX use (months) 19.0 (1.0–100)
Reason for switching
PNR 6.3 % (2/32)
SNR 46.9 % (15/32)
Intolerance 43.8 % (14/32)
Others 3.1 % (1/32)
Baseline CDAI (points) 185.1 ± 76.4
Baseline CRP (mg/dL) 0.74 (0.00–6.86)
Parametric variables are shown as mean ± standard deviation or
median (range)
IFX infliximab, PNR primary nonresponse, SNR secondary nonresponse, CDAI
Crohn’s Disease Activity Index, CRP C-reactive protein
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nonresponse to IFX treatment, while the patient with a
Rutgeerts score of i4 had all four risk factors.
Safety
In the assessment of up to 52 weeks, adverse events
were reported in a total of eight patients: pancytopenia,
sepsis, lupus-like reaction, hepatic function disorder, re-
current upper respiratory tract infection, ss-DNA anti-
body positive, catheter infection, and rash in one patient
each. ADA treatment was discontinued due to adverse
events in all seven patients except the one with the rash.
All events were resolved under observation after ADA
discontinuation or with treatment. There was no report
of malignant tumor development or death.
Discussion
ADA has been demonstrated effective against CD in the
CLASSIC I [11], CLASSIC II [13], GAIN [12], CHARM
[14], and EXTEND [15] placebo-controlled double-blind
studies. In Japan, its clinical efficacy was also demon-
strated in a placebo-controlled double-blind study [17],
and ADA has been available for clinical use since Octo-
ber 2010. However, limited reports to date are available
on usage data in real practice settings in Japan and other
Asian countries. Ishida, et al. [19] and Miyoshi, et al.
[20] reported results from a single center study with lim-
ited sample sizes of 28 and 45 subjects, respectively.
Therefore, we investigated the results of ADA treatment
for CD in real practice settings in this multicenter ob-
servational study. The remission rates from 4 to
52 weeks were similar to those reported by Ishida, et al.
[19] and Miyoshi, et al [20]. ADA was more effective in
real practice settings than in a clinical study with lim-
ited patients based on various exclusion criteria and a
CDAI of 220–450 [17].
This study identified CD location and baseline CDAI
as factors associated with ADA efficacy at 52 weeks. A
study by Cohen, et al. [30] also indicated a slightly higher
nonresponse rate in patients with the colonic type but
with no significant difference. To our knowledge, only the
current study demonstrated lower ADA efficacy in pa-
tients with the colonic type. We believe that the effects of
TNF-α may be greater in patients with lesions in the small
intestine, but no significant difference was detected on
multivariate analysis, so this issue requires further investi-
gation. Other factors including previous IFX treatment
21/62 46/62 47/62 48/62 41/62
a b
26/41 29/41 31/41 23/41
Fig. 2 Remission rate after up to 52 weeks of adalimumab treatment. The proportion of patients who achieved remission with a Crohn’s Disease
Activity Index (CDAI) < 150 is shown. a Remission rate of all 62 patients. b Remission rate of all 41 patients with a baseline CDAI≥ 150. Ten patients






















Fig. 3 Ongoing adalimumab (ADA) treatment rate. A total of 10
patients discontinued treatment due to primary nonresponse (n = 1),
secondary nonresponse (n = 2), or an adverse event (n = 7). The ADA
ongoing treatment rate at 52 weeks was 83.9 %
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[31, 32] and disease duration [33, 34] are reportedly asso-
ciated with ADA efficacy, but this study did not show a
significant difference in these factors. This may be due to
an insufficient sample size and the fact that more patients
had fewer disease activity events such as intolerance with
previous IFX treatment. The combined effect of immuno-
modulator and ADA has yet to be confirmed because of
conflicting reports [35–38], and no difference was noted
in this study either. Thus, prospective comparative studies
of ADA like the IFX SONIC study [39, 40] are needed.
The combined effect of an elemental diet and IFX has also
been reported [41–43], but no difference was observed in
this study. Serum ADA concentration and involvement in
efficacy of anti-adalimumab antibody (AAA) have been
highly reported recently [44–49], but we could not evalu-
ate these parameters in the current study.
We also investigated the ability of ADA to prevent
postoperative recurrence. Several reports have been pub-
lished to date in Europe or the US [25, 50–52], but there
are few reports from Asian countries. This study con-
firmed that ADA effectively prevented postoperative re-
currence in a small sample of 16 patients. While a meta-
analysis indicated the efficacy of anti-TNF-α antibody for
preventing postoperative recurrence [26], the use of anti-
TNF-α antibody has a cost-benefit performance issue [53]
and is recommended for patients at high risk and those in
Table 2 Comparison of remission and non-remission groups at 52 weeks
Remission (n = 41) Non-remission (n = 21) P value
Age (years) 32.1 ± 10.5 34.9 ± 10.1 0.3201a
Gender (male) 75.6 % (31/41) 71.4 % (15/21) 0.7648c
Disease duration (months) 87.0 (0.0–480.0) 144.0 (0.0–336.0) 0.3964b
Disease duration < 2 years 36.6 % (15/41) 23.8 % (5/21) 0.3962c
Colonic type 4.9 % (2/41) 23.8 (5/21) *0.0387c
Surgery 61.0 % (25/41) 66.7 % (14/21) 0.7837c
Extra fistula 30.0 % (12/40) 42.9 % (9/21) 0.3980c
Intra fistula 7.5 % (3/40) 9.5 % (2/21) >0.9999c
Perianal disease 46.3 % (19/41) 52.4 % (11/21) 0.7895c
Smoking 17.6 % (6/34) 16.7 % (3/18) >0.9999c
Concomitant use
5-Aminosalicylates 87.8 % (36/41) 100 % (21/21) 0.1569c
Steroids 9.8 % (4/41) 9.5 % (2/21) >0.9999c
Immunomodulators 22.0 % (9/41) 28.6 % (6/21) 0.7548c
Elemental diet 65.9 % (27/41) 57.1 % (12/21) 0.5829c
IFX experience
Experience with IFX 51.2 % (21/41) 57.1 % (12/21) 0.7895c
Double dose 28.6 % (6/21) 41.7 % (5/12) 0.4713c
Duration of IFX use (months) 19.5 (1.0–84.0) 10.0 (1.0–100) 0.7818b
Reason of switch 0.5700d
PNR 10.0 % (2/20) 0.0 % (0/12)
SNR 45.0 % (9/20) 50.0 % (6/12)
Intolerance 40.0 % (8/20) 50.0 % (6/12)
Other 5.0 % (1/20) 0.0 % (0/12)
CDAI at baseline (points) 169.5 ± 76.8 215.4 ± 67.2 *0.0236a
CRP at baseline (mg/dL) 0.70 (0.00–6.86) 0.88 (0.02–6.34) 0.4436b
Parametric variables are shown as mean ± standard deviation or median (range)
IFX infliximab, PNR primary nonresponse, SNR secondary nonresponse, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein
*P < 0.05
aStudent’s t-test; bMann-Whitney U-test; cFisher’s exact test; dChi-square test
Table 3 Predictors of remission at 52 weeks of adalimumab
treatment (multivariate analysis)
Factor Odds ratio (95 % CI) P value
CDAI at baseline 0.993 (0.985–1.000) 0.0577
Colonic type 0.207 (0.035–1.230) 0.0833
CI confidence interval, CDAI Crohn’s Disease Activity Index
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Table 4 Results of ADA treatment for the prevention of postoperative recurrence



































1 M 33 153 Ileocolonic ○ 43 × ○ ○ × 2 48 ○ 20 i0 ○
2 M 32 77 Ileocolonic ○ 18 ○ ○ ○ ○ 4 50 ○ 44 i4 ×
3 M 38 96 Ileocolonic × 23 ○ ○ × ○ 3 49 ○ 47 i0 ○
4 M 30 178 Ileo ○ 57 × ○ ○ × 2 46 × 37 i3 ×
5 M 29 3 Ileocolonic × 40 ○ × × ○ 2 40 ○ 28 i2 ×
6 M 50 276 Ileo × 49 × × ○ × 1 32 ○ 23 i0 ○
7 M 19 8 Ileocolonic × 15 ○ × × ○ 2 38 ○ 22 i0 ○
8 M 50 480 Ileocolonic ○ 23 × ○ ○ × 2 38 ○ 38 i1 ○
9 M 34 180 Ileo ○ 60 ○ × ○ × 2 31 ○ 8 i0 ○
10 M 33 120 Ileo × 240 × ○ × ○ 2 29 ○ 28 i2 ×
11 M 43 204 Ileocolonic × 73 × ○ ○ × 2 32 ○ - - -
12 M 47 36 Ileocolonic × 53 × ○ ○ ○ 3 24 ○ - - -
13 M 23 18 Ileocolonic × 22 × ○ × ○ 2 15 ○ 8 i0 ○
14 F 45 396 Ileocolonic × 82 × ○ ○ × 2 24 ○ 24 i3 ×
15 M 27 3 Ileocolonic × 10 × × × ○ 1 16 ○ 15 i0 ○
16 F 31 18 Ileocolonic × 38 × ○ × ○ 2 12 ○ 12 i0 ○
Total M/F:
14/2
35.3 140.4 4/12 31.3 % (5/
16)








2.1 32.3 93.8 %
(15/16)
25.3 - 64.3 % (9/
14)
Parametric variables as total are shown as mean or rates













whom relapse was observed in postoperative monitoring
[54]. The POCER study recently reported on the useful-
ness of postoperative risk factor–based therapeutic stratifi-
cation, endoscopic monitoring, and therapeutic
intensification [55]. However, in the POCER study, thio-
purine was used as the first-line treatment even for high-
risk patients, while the active care group with endoscopic
evaluation and therapeutic intensification had a relatively
high recurrence rate. A greater number of risk factors was
associated with a higher relapse rate. Our study also indi-
cated more risk factors in patients who showed endo-
scopic recurrence with a Rutgeerts score of i3 or i4.
Therefore, positive use of anti-TNF-α antibody may re-
quire consideration for high-risk patients. Recent studies
reported the usefulness of fecal calprotectin as a param-
eter in postoperative monitoring [56, 57]. Postoperative
monitoring and therapeutic optimization as consider-
ations of the burden of examination and cost-benefit rela-
tionship are required.
This study has several limitations. First, it had an in-
sufficient sample size of unselected patients with hetero-
geneous baseline characteristics in a real practice setting.
Therefore, it was difficult to determine the efficacy-
associated factors. Second, the assessment of prevention
of postoperative recurrence was made only in a small
group of 16 patients, the timing of ADA introduction
and endoscopic examination was inconsistent, and en-
doscopy was not performed for some patients. There-
fore, further larger-scale studies with strict evaluation
methods are required to validate our results.
Conclusions
Even with the above-mentioned limitations, we concluded
in this study that ADA effectively provided clinical remis-
sion and prevented postoperative recurrence of CD in real
practice settings.
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